[Therapeutic possibilities in KRAS-mutant lung adenocarcinoma]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• KRAS mutations are frequent gain-of-function alterations in lung adenocarcinoma (LADC), particularly in Western populations.
• Despite decades of research, direct inhibition of KRAS has been unsuccessful due to challenges in drug development.
• Previous indirect strategies targeting KRAS pathways have also yielded limited success.

Purpose of the Study:

• To review the predictive and prognostic significance of KRAS mutations in LADC.
• To summarize current and emerging therapeutic strategies targeting KRAS mutations in LADC.

Main Methods:

• Literature review of studies on KRAS mutations in LADC.
• Analysis of preclinical data for KRAS-targeted therapies.
• Summary of clinical trial outcomes for KRAS inhibitors.

Main Results:

• KRAS mutations have established predictive and prognostic value in LADC.
• Direct KRAS inhibitors have faced significant development hurdles.
• Emerging covalent inhibitors targeting specific KRAS mutations, such as KRAS G12C, demonstrate promising preclinical efficacy.

Conclusions:

• Targeting specific KRAS mutations represents a promising therapeutic avenue for LADC.
• Covalent KRAS G12C inhibitors are advancing as a potential treatment strategy.
• Further research is needed to fully elucidate the clinical utility of KRAS-targeted therapies.